Potential for Differential Diagnosis with Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in Experimental Hepatic Tumors

Investigative Radiology

Volumn 39, Issue 2, 2004, Pages 80-88

  Tsuda, Natsuko ^a   Kato, Naoki ^a   Murayama, Chie ^a   Narazaki, Michiko ^a   Yokawa, Takashi ^a  

^a Nihon Schering   (Japan)

Author keywords

Animal; Contrast agent; Hepatocellular carcinoma; MRI

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOXETIC ACID; NITROSOMORPHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER TUMOR; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

EID: 0942265569     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000105331.11373.c0     Document Type: Article

References (27)

1. Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics. 2003;23:107-121.
2. Karabacakoglu A, Karakose S, Cil AS, et al. Contrast media-enhanced power doppler sonography for evaluation of hemangiomas and malignant tumors in the liver. J Gastroenterol Hepatol. 2003;18:92-98.
3. Chen RC, Chen WT, Liao LY, et al. Intravenous contrast-enhanced doppler sonography and intra-arterial carbon dioxide-enhanced sonography in the assessment of hepatocellular carcinoma vascularity before and after treatment. Acta Radiol. 2002;43:4:411-414.
4. Furuse J, Maru Y, Mera K, et al. Visualization of blood flow in hepatic vessels and hepatocellular carcinoma using B-flow sonography. J Clin Ultrasound. 2001;29:1:1-6.
5. Kato H, Kanematsu M, Matsuo M, et al. Atypically enhancing hepatic cavernous hemangiomas: high-spatial-resolution gadolinium-enhanced triphasic dynamic gradient-recalled-echo imaging findings. Eur Radiol. 2001;11:2510-2515.
6. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium-and ferumoxides-enhanced MR imaging of the liver. Radiology. 2002;222:73-80.
7. Yu JS, Kim KW, Park MS, et al. Transient peritumoral enhancement during dynamic MRI of the liver: cavernous hemangioma versus hepatocellular carcinoma. J Comput Assist Tomogr. 2002;26:3:411-417.
8. Hussain HK, Londy FJ, Francis IR, et al. Hepatic arterial phase MR imaging with automated bolus-detection three dimensional fast gradient-recalled-echo sequence: comparison with test-bolus method. Radiology. 2003;226:558-566.
9. Muramatsu Y, Nawano S, Takayasu K, et al. Early hepatocellular carcinoma: MR imaging. Radiology. 1991;181:209-213.
10. Inoue E, Kuroda C, Narumi Y, et al. Magnetic resonance imaging-histologic correlation of small hepatocellular carcinoma and adenomatous hyperplasias. Invest Radiol. 1993;28:8:691-697.
11. Lencioni R, Mascalchi M, Caramella D, et al. Small hepatocellular carcinoma: differentiation from adenomatous hyperplasia with color doppler US and dynamic Gd-DTPA-enhanced MR imaging. Abdim Imaging. 1996;21:41-48.
12. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast agent. Magn Reson Med. 1991;22:233-237.
13. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol. 1997;7:275-280.
14. Bollow M, Taupitz M, Hamm B, et al. Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol. 1997;7:126-132.
15. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177-183.
16. Schmitt-Willich H, Brehm M, Ewers Ch LJ, et al. Synthesis and physicochemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg Chem. 1999;38:1134-1144.
17. Stem W, Schick F, Kopp AF, et al. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol. 2000;41:255-262.
18. Fujita M, Yamamoto R, Takahashi M, et al. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging. 1997;7:4:768-770.
19. Ni Y, Marchal G, Yu J, et al. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging. 1994;4:3:355-363.
20. Ni Y, Marchal G. Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of Preclinical animal experiments. Top Magn Reson Imaging. 1998;9:3:183-195.
21. RAS plasma. Int J Cancer. 2001;93:441-444.
22. Low-Baselli A, Huber W. W, Kafer M, et al. Failure to demonstrate chemoprevention by the monoterpene perillyl alcohol during early rat hepatocarcinogenesis: a cautionary note. Carcinogenesis. 2000;21:10: 1869-1877.
23. Robichova S, Slamenova D. Effect of vitamins C and E on cytotoxicity induced by N-nitroso compounds, N-nitrosomorpholine and N-methyl-N′ -nitro-N-nitrosoguanidine in Caco-2 and V79 cell line. Cancer Lett. 2002;182:11-18.
24. Pascolo L, Cupelli F, Anelli P. L., et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun. 1999;257:746-752.
25. van Montfoort JE, Stieger B, Meijer DK, et al. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide oatpl. J Pharmacol Exp Ther. 1999;290: 153-157.
26. Itai Y. MRI and MRS in the diagnosis of cancer. Gan To Kagaku Ryoho. 1989;16:3:2:639-645.
27. Perkins AB, Imam K, Smith WJ, et al. Color and power doppler sonography of liver hemangiomas: a dream unfulfilled? J Clin Ultrasound. 2000;28:4:159-165.